Unity Biotechnology Inc. Stock News

Strategic realignment to focus capital resources on clinical programs and extend cash runway into Q1 2023

Unity Biotechnology Inc (UBX) shares closed 0.7% lower than its previous 52 week low, giving the company a market cap of $79M. The stock is currently down 73.7% year-to-date, down 75.2% over the past 12 months, and down 91.7% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 97.1% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 147.8% The company's stock price performance over the past 12 months lags the peer average by 140.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseas

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from December 7, 2021, through December 21, 2021, the Compensation Committee of the Board of Directors (the Board) granted a new employee a stock-based award covering an aggregate of 4,500 shares of UNITY common stock, including options to purchase an aggregate of 4,500 shares of UNITY common stock. The stock-based award was granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4) .

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseas

During the last session, Unity Biotechnology Inc. (NASDAQ:UBX)’s traded shares were 1.21 million, with the beta value of the company hitting 0.12. At the end of the trading day, the stock’s price was $1.54, reflecting an intraday loss of -12.50% or -$0.22. The 52-week high for the UBX share is $9.78, that puts it down … Does Unity Biotechnology Inc. (NASDAQ: UBX) Still Look Attractive After A -18.09% Selloff Last Week? Read More »

Unity Biotechnology (NASDAQ:UBX)s stock had its outperform rating reaffirmed by equities researchers at Wedbush in a research note issued on Wednesday, RTT News reports. They currently have a $4.00 target price on the stock. Wedbushs target price points to a potential upside of 127.27% from the stocks previous close. Other equities research analysts have also []

Unity Biotechnology Inc. (NASDAQ:UBX) shares, rose in value on Wednesday, 11/24/21, with the stock price down by -1.28% to the previous day’s close as strong demand from buyers drove the stock to $2.32. Actively observing the price movement in the last trading, the stock closed the session at $2.35, falling within a range of $2.26 … Unity Biotechnology Inc. (NASDAQ: UBX) Stock Forecast: 12.00 USD Or More! Read More »

Walleye Trading LLC purchased a new stake in Unity Biotechnology, Inc. (NASDAQ:UBX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 16,378 shares of the companys stock, valued at approximately $76,000. A number of other institutional investors and hedge funds have also recently added []

Schonfeld Strategic Advisors LLC bought a new position in shares of Unity Biotechnology, Inc. (NASDAQ:UBX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 17,900 shares of the companys stock, valued at approximately $83,000. Other hedge funds also recently made changes []

Mizuho upgraded Unity Biotechnology Inc (NASDAQ: UBX) to Buy from Neutral with a price target of $7, up from $5 after Unity announced longer-term Phase 1 data for UBX1325 in diabetic macular edema

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases

Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and wet age-related macular degeneration (AMD), for who

16 th Annual Citi BioPharma Conference on September 8-10, 2021

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases